A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.

ABSTRACT:

Background

LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19.

Methods

In this platform trial of therapeutic agents, we randomly assigned hospitalized patients who had Covid-19 without end-organ failure in a 1:1 ratio to receive either LY-CoV555 or matching placebo. In addition, all the patients received high-quality supportive care as background therapy, including the antiviral drug remdesivir and, when indicated, supplemental oxygen and glucocorticoids. LY-CoV555 (at a dose of 7000 mg) or placebo was administ

SUBMITTER: ACTIV-3/TICO LY-CoV555 Study Group 

PROVIDER: S-EPMC7781100 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature